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people with psoriasis. Methods: We used the Taiwan’s National Health Insurance 
Research Database to conduct a nationwide population-based cohort study to assess 
the risk of incident CKD and ESRD in people with psoriasis and to further evalu-
ate the respective risk estimates in those with mild and severe psoriasis based 
on treatment patterns. Results: A total of 4,633 psoriatic patients and 922,534 
nonpsoriatic controls were included. Severe psoriasis, but not mild psoriasis, was 
an independent risk factor of incident CKD and ESRD (adjusted hazard ratio being 
1.90 (95% confidence interval 1.33-2.70) and 2.97 (95% confidence interval 1.72-
5.11), respectively) after adjustment for potential confounders including age, gender, 
comorbidities, and used of nonsteroidal anti-inflammatory drugs (NSAIDs). Severe 
psoriasis remained an independent risk factor of incident CKD and ESRD after vari-
ous sensitivity analyses after adjusting for the presence of osteoarthritis and/or 
rheumatoid arthritis, use of methotrexate and/or cyclosporine, and chronic use 
of NSAIDs for at least 2 months. Psoriatic arthritis was an effect modifier for CKD 
and ESRD. ConClusions: The associations of severe psoriasis with CKD and ESRD 
should be recognized. Assessment of renal function and avoidance of long-term 
use of nephrotoxic drugs shall be implemented in the integrative care for patients 
with severe psoriasis.
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objeCtives: To assess co-morbidity, quality of life (QOL), work/productivity loss, 
and medical resource utilization (MRU) in patients suffering from glaucoma in 
Brazil. Methods: Patients self-reported data were collected from 2011-2012 
National Health and Wellness Survey (NHWS -Kantar Health global self-reported 
general population survey in healthcare). QOL was measured by the physical com-
ponent score (PCS) and mental component core (MCS)of the Short Form-12 (SF-12) 
(mean score of 50 for general population). Loss of work/productivity was measured 
by the validated Work Productivity and Activity Impairment (WPAI) instrument. 
MRU was measured by healthcare provider, emergency room (ER) visits and hospi-
talization in the past 6 months.Comparisons were made between respondents who 
were diagnosed with glaucoma vs. respondents without glaucoma (non-glaucoma 
group). Since glaucoma typically affects the adult population, respondents with an 
age of 35 and above were included in the analysis. Results: Among 24,000 survey 
respondents, 242 (1.0%)respondents were diagnosed with glaucoma. The average age 
in the glaucoma group was 53.5 years and 48.2% were male compared to the non-
glaucoma group where average age was 51.6 years with 47.8% male. The Glaucoma 
group reported more co-morbidities, lower mean PCS scores (46.3 vs. 49.4) and MCS 
scores (45.6 vs. 49.0), more healthcare providers visits (93.7%vs.77.4%), ER visits 
(29.6%vs19.0%) and hospitalizations (17.5%vs.9.7%) in the past 6 months compared 
to non-glaucoma group. Also, the glaucoma group reported 36.5% work/productiv-
ity loss (absenteeism and presenteeism) and 33.5% impairments in daily activity 
compared to 17.5% and 22.1% in non-glaucoma group. All comparisons in QOL, 
MRU, and work/productivity loss between two groups were statistically significant 
at P< 0.05. ConClusions: From the Brazil NHWS results, glaucoma patients suffer 
from impairments in quality of life, work/productivity loss,more co-morbidities 
and use of medical services. Findings indicate that glaucoma can have a statistical 
significant impact and negative impact on QOL, MRU and work productivity for 
patients suffering from the disease and for the healthcare system.
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objeCtives: Worldwide, glaucoma is the second highest cause of blindness. 
Surgery is the treatment of choice when medications fail to control intraocu-
lar pressure (IOP). This systematic literature review and meta-analysis aimed to 
compare efficacy and safety of the common surgical options available for pri-
mary angle closure glaucoma (PACG). Methods: Studies with PACG patients 
who underwent trabeculectomy, phacotrabeculectomy or phacoemulsification 
were screened and included from electronic databases. The outcomes compared 
were IOP (24 months), postoperative angle opening distance (AOD), postoperative 
trabecular-ciliary process distance, postoperative anterior chamber depth (ACD), 
synechial angle closure all at 1 year, best corrected visual acuity (BCVA) at 1 year 
and 2 years, and intra- and post-operative complications of the surgery like worse 
logarithmic minimal angle resolution BCVA, progression of glaucomatous optic 
neuropathy, progression of glaucomatous visual field at 2 years. Critical appraisal 
of studies was carried out using Cochrane’s Risk of Bias tool. Meta-analysis of 
clinical trials was conducted using RevMan v5.1, through pooling of medically 
controlled and uncontrolled glaucoma patients where available. Results: Of the 
704 studies that were screened, five randomised clinical trials were included. 
Pooled analysis of two studies showed IOP at 24 months was better controlled by 
phacotrabeculectomy (mean difference 1.46 [95%CI 0.24,2.67]). Post-operative AOD 
and ACD results favoured phacoemulsification (mean difference 123.60 [95%CI 
51.46,195.74] and 230.60 [95%CI 106.30,354.90] respectively). The post-operative 
complications showed risk ratio of 0.07 (95%CI 0.01,0.34) showing fewer com-
plications in phacoemulsification patients. The remaining outcomes showed no 
significant results. Phacoemulsification had significantly lesser complications 
than trabeculectomy, with risk ratio of 0.08 (95%CI 0.01,0.60). The analyses of the 
observational and economic studies are being carried out, the results of which will 
be included in the poster. ConClusions: The results show that while phacotrab-
eculectomy has better IOP control than phacoemulsification, the latter has higher 
safety than both phacotrabeculectomy and trabeculectomy.
use of these drugs increases by 18.0%, Fluoxetine is responsible for the growth 
of 88.5 % in this incidence, with a confidence interval of 95 % and standard error 
of 2%. ConClusions: It was identified that the main molecule used for depres-
sion, in the sample analyzed, was fluoxetine and the age with higher incidence of 
purchases of these drugs is between 20 and 50 years. As WHO data (World Health 
Organization), depression will be the most common disease in the world in 2030. 
The relationship between doctor and patient has a fundamental importance in 
successful treatment. Thus, the patient monitoring is extremely important to con-
trol the disease in the country.
Pmh51
inteGrated clinical Pathway in SchizoPhrenia
Colombo GL1, Valentino MC2, Di Matteo S2, Bruno GM2
1University of Pavia, Milan, Italy, 2S.A.V.E. Studi - Health Economics & Outcomes Research, Milan, 
Italy
objeCtives: mental disorders are a significant problem of public health, espe-
cially for disability they generate during adulthood. They strongly influence qual-
ity of life for patients as well as having important impacts on society and mental 
health services, creating a significant economic problem for the health system 
and for patient. Methods: an integrated clinical pathway (PDTA) for patient with 
schizophrenia has been validated by a group of Italian medical experts. This clinical 
governance tool, enables to organize and integrate activities and interventions in 
a context where, several specialties, professions and areas of action (hospital and 
territorial care) are involved. Results: drug acquisition costs are not the highest 
costs in the schizophrenia management. The highest costs are related to: frequent 
hospitalization, residential care costs, loss of individuals productivity, high costs 
for caregiver. The aim of our work is to offer, to the different actors involved in 
the schizophrenia treatment management, a governance tool (PDTA) that allow: to 
manage the treatment variability, to monitor the resource utilization, to monitor the 
adherence and to improve the quality of processes and outcomes. Also the schizo-
phrenia PDTA, promoting the early use of antipsychotics LAI, answer to the main 
unmet needs in the pathology management: the frequent relapses, the functional 
status preservation and the maintenance of good quality of life. An indicators set 
was validated to monitor the correct adoption of PDTA in order to generate savings 
and better manage the cost of disease. ConClusions: thanks to integrated clinical 
pathway all the actors involved in treating mental disorders are able to outline, the 
best clinical pathway practicable, compared to schizophrenia, in order to optimize 
resources and costs. A desirable perspective is the adoption of the clinical pathway 
at the regional level and in the future also at the national level.
SenSory SyStemS diSorderS – clinical outcomes Studies
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objeCtives: To evaluate safety and efficacy of Timolol and Brimolol 
(Brimonidine+Timolol) and study effect of aerobic exercise on intra ocular ten-
sion (IOT) in timolol treated patients. Methods: A prospective study including 90 
cases of newly diagnosed primary open angle glaucoma (POAG) from ophthalmology 
inpatients divided into 3 groups: 1-Timolol, 2-Timolol (Exercise) and 3-Brimolol.Each 
patient was administered with topical drugs followed up every 15th day. Efficacy of 
drugs were tested based on IOT measurement by Non-contact tonometer at an inter-
val of 15 days and safety on the basis of ADR check list, fundoscopy and slit lamp 
examination with tear film break up time and tear gland secretion (schirmer test).
In group 2, patients were advised to do 30 min exercise daily for 1 month. Results: 
Mean reduction in IOT was statistically significant with values as 2.7, 5& 7.9 mmHg 
and 6, 9&11 mmHg in group 1, 2 and 3 at 15th and 30th day. Frequency of ADR in 
group 1, 2&3 was 36%, 30% &40% respectively with the most frequent ADR in group 
1&2 as burning of eyes (50%) & in group 3 as dryness (22%).Effect of brimolol on 
schirmer test was significant with a mean difference of 4.33 mmHg. Frequency of 
patients missing ophthalmic doses were 60%, 48% &48% and drop out treatment 
rate was 9%,9%& 14% in group 1, 2& 3 respectively with monetary reason (most com-
mon).Most frequent cause of missing ophthalmic doses was ADR (30%) in group 1&2 
and monetary reason (43%) in group 3(predominantly in lower class).GQR-15 score 
was 35, 29&30.5 in group 1, 2 &3. ConClusions: Brimolol provides superior IOT 
lowering to timolol but is less well tolerated.Exercise along with timolol provides 
superior IOT lowering effect to timolol alone & is better tolerated, has superior visual 
QOL with reduced frequency of missed ophthalmic doses.Brimolol substantially 
reduces tear gland secretion.
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objeCtives: Psoriasis is a chronic inflammatory dermatosis that has been associ-
ated with various cardiovascular and metabolic comorbidities, including myocardial 
infarction, stroke, and diabetes mellitus. Recently, there are studies reporting the 
association of psoriasis with renal diseases. This study aimed to evaluate the risk 
of incident chronic kidney disease (CKD) and end-stage renal disease (ESRD) in 
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objeCtives: The recent publication of the DRCR.net Protocol T study, sponsored by 
the National Institutes of Health (NIH), is the first head-to-head trial of ranibizumab 
(Lucentis, Genentech), aflibercept (Eylea, Regeneron), and bevacizumab (Avastin, 
Genentech). The lack of head-to-head data of the anti-vascular endothelial growth 
factor treatments of diabetic macular edema (DME) has led to a dependency on indi-
rect comparisons of treatments for DME. To update the current literature, an indi-
rect comparison of the effectiveness of all treatments for diabetic macular edema 
(DME) in the last 10 years was undertaken, and includes results from the Protocol 
T study. Methods: A comprehensive search was conducted to identify relevant 
studies published in the last 10 years on MEDLINE, Embase, the Cochrane Library, 
and CINAHL. Selective studies were synthesized and assessed for quality. Studies 
with too few patients (less than 30) or with a quality score of 25% or lower were 
excluded. A random-effects model was used to pool effectiveness and to examine 
heterogeneity. Results: At the time this abstract was published, the results were 
still being finalized. It is expected that the results will show a greater improvement 
in best-corrected visual acuity (BCVA) for patients treated with aflibercept com-
pared to the other treatments, similar to previous meta-analyses. Unlike recent 
previous meta-analyses, this study will provide a comparative assessment of all 
other treatments for diabetic macular edema, including laser and steroids such as 
dexamethasone and triamcinolone. ConClusions: This study seeks to clarify and 
update the current literature with the results of an indirect comparison. Results 
and conclusions are forthcoming and will be presented at the ISPOR 18th Annual 
European Congress.
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objeCtives: Drug survival (time to drug discontinuation) can be interpreted as a 
composite measure of effectiveness, safety and tolerability. The aim of the present 
study was to compare the drug survival between adalimumab and etanercept in 
patients diagnosed with psoriasis (PsO) in Sweden. Methods: Patients with PsO 
(ICD-10; L40.0, L40.4-L40.5, and L40.9) starting their first treatment of etanercept or 
adalimumab between 2009 and 2014 were identified in the publicly available Swedish 
Drug Prescribed Registry and record-linked to the Swedish National Patient Registry. 
Data were collected through 31 December 2014. Drug discontinuation was defined 
as if the patient did not pick upa prescription at the pharmacy for the same treat-
ment within 90, 100 and 120 days after the end of the previous dispensing episode. 
Kaplan-Meier curves and Cox regression was used with adjustment for sex, calendar 
year and age at initiation. Results: A total of 3,640 PsO patients were utilizing their 
first etanercept (48.3%) or adalimumab (51.7%) treatment between 2009 and 2014 in 
Sweden. There were statistically significant differences in calendar year (p< 0.001) and 
age at initiation (p= 0.014), but not for sex (p= 0.081) between the two treatments. Drug 
survival was statistically significant higher for etanercept compared to adalimumab 
when using 90, 100 but not for 120 days as the definition for discontinuation. Following 
adjustment for calendar year, sex and age at initiation, the risk of discontinuation 
was lower in etanercept compared to adalimumab when using 90 and 100 days as the 
definition time (90 days; HR 0.83, 95% CI 0.76-0.92; 100 days HR 0.86; 95% CI 0.77-0.96; 
120 days HR 0.92 95% CI 0.81-1.04). Also, increased age at initiation, calendar year, and 
male were all independent factors for a lower discontinuation rate. ConClusions: 
Drug survival rates were higher for etanercept compared with adalimumab among 
PsO patients in a nationwide real world setting in Sweden.
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objeCtives: SSTIs are an emerging cause of outpatient visits and hospitalizations, 
due to the dramatic rising of antimicrobial resistance and severity of the infection. 
This study aimed to analyze the healthcare profile of patients with SSTIs in the 
real clinical practice and to determine the total cost of the disease. Methods: 
Starting from ARNO Observatory database (13 million citizens), a cohort of patients 
with SSTIs, with available, complete and good quality data on pharmaceutical pre-
scriptions, diagnostic procedures and hospital discharges, was selected. The accrual 
period lasted from the January 1st to December 31st 2012. Every single patient was 
followed for 1 year, to identify events, healthcare services associated to SSTIs and 
their costs. A focus on Linezolid was made to evaluate the proper length of treatment, 
both in hospital (assuming hospitalization days equivalent to prescriptions) and in 
community care (pharmaceutical prescriptions). Results: Of 2.216 patients with 
SSTIs (67% men, mostly aged ≤ 25), 1.771 (79,9%) received at least one drug prescrip-
tion: “Beta-lactam antibacterials” the most prescribed (40%) and “Other antibiotics” 
the most expensive (1.340€ ), where Linezolid resulted the most used (106 patients). 
According to requirements, its therapy length is appropriate if it lasts 10 to 14 days 
(600mg twice daily). The outpatient oral cycle therapy lasted on average for 17,8 days 
and the IV formulation for 9,8 days, while hospitalization days were on average 7. 
Ordinary and daily hospitalizations were the most expensive healthcare services 
(on average 4.718€ /patient). Linezolid widely contributes to pharmaceutical costs 
(622€ /patient), both for IV and for oral formulation, respectively mean expenditure 
914€ and 686€ during the one-year follow-up. ConClusions: The community use 
of Linezolid is bordering on authorized dosages and raises costs of patients with 
SSTIs. This must be considered by LHUs and Physicians when assessing health-
care profiles of SSTIs disease, estimating costs of illness and improving clinical 
governance.
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objeCtives: Currently, there is no study reporting synergistic skin whitening 
potential of green tea and lotus in healthy humans. The aim of this study was 
to investigate the in-vitro anti tyrosinase activity of green tea and lotus extracts, 
consequently to determine the actual potential efficacy of the topical formulations 
in healthy humans in a 60 days treatment course. Methods: Thirty three healthy 
human subjects were enrolled in an approved single-blind, placebo-controlled, 
split-face trial. Each group with eleven subjects applied green tea (GT), lotus (L) or 
green tea plus lotus (GT-L) multiple emulsions over 60 days treatment period. The 
subjects applied placebo treatment on one side of the face while active treatment 
on other half of the face and they were educated to apply the formulations once 
daily at bed time. Clinical objective evaluations were performed with a non-invasive 
biometrology probe at baseline, day 15, 30, 45 and day 60. Results: Melanin index-
MI measured for each treatment on different time intervals and it was statistically 
evident that combined treatment of green tea and lotus offered more benefit than 
single treatments (P < 0.001). ConClusions: It was concluded that green tea plus 
lotus could be explored further for the treatment of pigmentation disorders.
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objeCtives: City of Harkány has a traditional and well recognized thermal water 
spa since early 19thcentury, the oldest one in Hungary. The aim of our study was to 
compare the effect of traditional PUVA therapy to the effect of PUVA therapy comple-
mented with Harkány water therapy on psoriasis patients. Methods: Patients with 
psoriasis were recruited with the help of dermathologists (February-November 2014). 
We identified two patient groups. The traditional PUVA treatment was conducted in 
the Hospital of Komló (N= 25 patients, average age: 54.7 years), the PUVA treatment 
complemented with Harkány thermal water treatment was conducted in the Spa 
Hospital in Harkány (N= 52 patients, average age: 57 years). The length of the treatment 
was 3 weeks. The efficacy of the treatment was assessed by Psoriasis Area Severity 
Index (PASI scores). Results: Patients treated with traditional PUVA therapy had 
a starting PASI score of 10.1, while patients treated with PUVA complemented with 
Harkány water therapy had the starting PASI score of 8.2. After the three weeks long 
treatment patients treated with traditional PUVA treatment got a 50% better PASI 
score vs. the starting point. In the other group, where patiants were treated with 
PUVA complemented with Harkány water the PASI score showed an improvement 
bigger than 75%. The change is 5.2 points at the traditional and 6.2 points at the 
Harkány water treatment, and the derogation is significant (p< 0,005), than in the con-
trol group. ConClusions: The PUVA therapy complemented with Harkány thermal 
water therapy resulted in an increased improvement in the patients’ quality of life, 
based on the PASI scores. It is advisable to rethink the psoriasis therapy protocol, due 
to the increased improvement of the patients treated with Harkány thermal water.
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objeCtives: Compare the efficacy of therapies in the treatment of visual impair-
ment due to diabetic macular edema. Methods: A systematic review was con-
ducted to identify relevant randomized control trials (RCTs). RCTs reporting 6- or 
12-month results for ranibizumab, aflibercept, laser or sham were included. The 
analysed outcomes were best-corrected visual acuity (BCVA) measured as the 
proportion of patients gaining at least 10 letters or 15 letters. Efficacy compari-
sons were made using a Bayesian network meta-analysis with random treatment 
effects adjusting for baseline BCVA. Results: The analysis included 2634 patients 
from 10 RCTs (including DRCR-net Protocol T). For the percentage of patients who 
gained ≥ 10 letters, ranibizumab 0.5 mg pro re nata(PRN) was numerically superior 
to aflibercept (OR, 1.6; 95% credible interval [CrI], 0.6–5.4). The odds of gaining ≥ 
15 letters were the same for ranibizumab 0.5 mg PRN and aflibercept 2q8 (OR, 1.0; 
95% CrI, 0.3–5.9 for PRN). Similar findings were found for ranibizumab 0.5 mg treat 
and extent (T&E). The probability that ranibizumab 0.5 PRN was a better treatment 
than aflibercept was 84% for patients gaining ≥ 10 letters and 51% for patients 
gaining ≥ 15 letters. The odds-ratio of gaining ≥ 10 letters with ranibizumab 0.5 mg 
(PRN or T&E) vs. 0.3 mg PRN was 2.3 (95% CrI: 0.5-16.6) and 2.0 (95% CrI: 0.4-30.7) 
for ≥ 15 letters. The probability that ranibizumab 0.5 mg was superior to 0.3 mg 
PRN was 89% for patients gaining ≥ 10 letters and 82% for patients gaining ≥ 15 
letters. ConClusions: Ranibizumab 0.5 mg patients had a higher probability of 
gaining ≥ 10 letters than aflibercept patients and had similar probabilities of gaining 
≥ 15 letters as aflibercept. Ranibizumab 0.5 mg has a higher probability of being the 
best treatment than ranibizumab 0.3 mg PRN.
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